The huge funding gap for European biotech is structural. European institutional investors like pension funds allocate only 0.02% of their balance sheets to venture, compared to 2% in the US. This factor-of-100 difference creates a major hurdle for the ecosystem's ability to retain its champion companies.

Recent billion-dollar successes in the French biotech ecosystem, such as Abivax and Medincel, are largely credited to their management teams. These leaders often have significant experience working in the US and other countries. This global perspective enables them to develop assets for a worldwide market, navigate different regulatory environments, and attract international funding, breaking the mold of previously localized French biotechs.

Despite positive signs like successful IPOs and upsized follow-on financings, the biotech market's recovery is fragile. Geopolitical conflicts, inflation fears, and interest rate uncertainty create significant macroeconomic volatility. This external pressure could scuttle the newfound positive momentum, similar to the market impact seen at the start of the Ukraine-Russia war.

Europe's decentralized biotech ecosystem offers a major operational advantage over hubs like Boston. Lower competition for talent, lab space, and clinical trial sites allows startups to operate at 50% of the cost, coupled with pre-money valuations that are often 40% lower, creating significant capital efficiency.

Unlike their US counterparts, European biotechs have less access to large venture funds. This forces a culture of extreme capital efficiency and discipline. This need to be "cleverer, smarter with less people and less money" is a defining feature and potential advantage of the European ecosystem.

The coalition's core mission is to prevent the exodus of successful biotechs to the US. By building a stronger capital market, they aim to keep champion companies like Argenx headquartered and operating in Europe, ensuring economic value, market capitalization, and tax revenues benefit the region, not the US.

For the first time in a decade, European equities have broken out of their long-term trend of a widening valuation discount versus the US. Historically, such breakouts signal the beginning of a sustained, multi-year period where this valuation gap narrows significantly from its current 23%.

The $10 billion sale of Metsera to Pfizer highlights a massive valuation arbitrage opportunity in Europe. The company, funded by US VCs, derived significant value from an asset that originated from a London university spinout. This core asset was acquired for only $34 million upfront, demonstrating that European science can be undervalued and represents a source of hidden gems for savvy investors.

The future biotech landscape is not US vs. China, but a "multipolar" world where savvy companies operate as "hybrid biotechs." They will selectively build bridges, cherry-picking talent, capabilities, and operational models across the US, Europe, and China to accelerate development.